Trial Profile

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Oct 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avutometinib (Primary) ; Defactinib (Primary)
Indications Adenocarcinoma; Ovarian cancer; Peritoneal cancer
Focus Proof of concept; Registrational; Therapeutic Use
Acronyms RAMP 201
Sponsors Verastem Oncology

Most Recent Events

02 Oct 2026 Results presented in a Verastem Oncology Media Release.
28 Sep 2026 According to a Verastem Oncology media release, two-year long-term results from the Phase 2 RAMP 201 study were published in the Gynecologic Oncology.
28 Sep 2026 Results published in a Verastem Oncology Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com